PRF Technologies Ltd. is facing a critical moment as it has received a delisting notice from Nasdaq. The company announced on November 12, 2026, that it has requested a hearing to appeal this determination after its stock price fell below the minimum requirement.

The Nasdaq Listing Qualifications Department notified PRF Technologies that its ordinary shares had been trading below $1.00 for 30 consecutive business days. This situation arose from September 24, 2026, to November 4, 2026, violating Nasdaq Listing Rule 5550(a)(2).

PRF Technologies is a company focused on pharmaceutical preparations, specifically reformulating established therapeutics and developing AI-driven energy optimization technologies. This recent development is significant not only for PRF but also for the broader pharmaceutical industry, where compliance with listing standards is crucial for maintaining investor confidence and market presence.

Background

PRF Technologies Ltd. operates under the ticker symbol PRFX on the Nasdaq exchange. The company, classified under the Standard Industrial Classification code 2834, specializes in pharmaceutical preparations. Its recent filings include multiple 6-K forms, with the latest being filed on November 12, 2026.

What the Filing Says

The filing states, "On November 9, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the closing bid price of its ordinary shares had been below US$1.00 per share for 30 consecutive business days." The company has until November 16, 2026, to request a hearing, which it has done.

Impact

This situation may affect the company's shareholders, employees, and stakeholders who rely on its continued presence in the market. The interim CEO, Efraim Cohen-Arazi, reassured that the notice does not impact current business operations and highlighted the company's cash position and ongoing projects.

What's Next

The company has requested a hearing before a Nasdaq Hearings Panel, which will allow it to present a plan to regain compliance with the minimum bid price requirement. The hearing request stays any suspension or delisting action, allowing PRF's ordinary shares to continue trading on Nasdaq while awaiting the Panel's decision.